Kenvue Inc. (NYSE:KVUE) Shares Purchased by SRS Capital Advisors Inc.

SRS Capital Advisors Inc. increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 67.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,418 shares of the company’s stock after purchasing an additional 571 shares during the quarter. SRS Capital Advisors Inc.’s holdings in Kenvue were worth $30,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Asahi Life Asset Management CO. LTD. grew its stake in Kenvue by 34.2% during the 4th quarter. Asahi Life Asset Management CO. LTD. now owns 16,830 shares of the company’s stock worth $359,000 after purchasing an additional 4,290 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Kenvue by 67.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 8,718 shares of the company’s stock worth $185,000 after purchasing an additional 3,519 shares in the last quarter. Metis Global Partners LLC grew its stake in Kenvue by 34.6% during the 4th quarter. Metis Global Partners LLC now owns 82,232 shares of the company’s stock worth $1,756,000 after purchasing an additional 21,125 shares in the last quarter. US Bancorp DE grew its stake in Kenvue by 66.9% during the 4th quarter. US Bancorp DE now owns 276,134 shares of the company’s stock worth $5,896,000 after purchasing an additional 110,680 shares in the last quarter. Finally, SVB Wealth LLC acquired a new position in Kenvue during the 4th quarter worth $478,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Up 1.2 %

Shares of NYSE KVUE opened at $23.46 on Friday. The stock has a market cap of $44.83 billion, a PE ratio of 44.25, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The business has a 50-day moving average price of $21.64 and a 200 day moving average price of $22.32.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.50%. Kenvue’s payout ratio is 154.72%.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Piper Sandler increased their price objective on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. UBS Group dropped their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Citigroup dropped their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Finally, Barclays dropped their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $23.75.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.